Biopharma's hot topic - weight loss drugs – will take center stage when Cantor’s Louise Chen speaks at the Seeking Alpha Investing Summit on June 18, 2024. Register below to attend and learn about how the GLP-1 drug market is anticipated to become the best-selling drug class in 2024. https://ow.ly/YW4P50SiQ4u
Cantor Fitzgerald’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Takeda signs option deal for TKI inhibitor; Enveda's $55M raise >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #productmarketing
To view or add a comment, sign in
-
#Biopharma deal values are surging compared to 2022, but several uncertainties are weighing on dealmaking sentiment. Explore how M&A is affecting #dealmaking tailwinds in the biopharma industry. Read now: https://bit.ly/47Eh05R #PharmaDeals #ProtectionLink #ForecastLink
To view or add a comment, sign in
-
-
Thoughts on this? >> Takeda signs option deal for TKI inhibitor; Enveda's $55M raise >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical
Takeda signs option deal for TKI inhibitor; Enveda's $55M raise
https://endpts.com
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/F10z2R
To view or add a comment, sign in
-
“This is a story about two big dominators here: Eli Lilly and Novo Nordisk. Lilly and Novo are going to be dominating this space in the foreseeable future,” said our Head of BioPharma Research, Rahul R Jasuja, PhD on Schwab Network. With a surge of GLP-1 drugs into the market and heightened interest, Rahul anticipates that Eli Lilly and Company (LLY) and Novo Nordisk (NVO) will maintain their stronghold over the next decade. During the interview, Rahul also delves into the proprietary process behind our GLP-1 monitor tool, which enhances research for investors by extracting valuable insights from analyst reports, leading to a robust and high-quality market consensus and offering more accurate longer-term forecasts. Watch the interview for Rahul's outlook on the GLP-1 drug market, insights on other emerging players to follow, and more: https://hubs.li/Q02rKzXH0
Biotech’s Next Gold Rush: Weight-Loss Drugs | The Watch List| Schwab Network
schwabnetwork.com
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/0fcxGg
To view or add a comment, sign in
-
#Newsupdate ✓For Exparel RLD by Pacira (Bupivacaine liposome injectable suspension), first generic was approved recently by FDA 🌀ANDA#214348 by Hengrui Pharma 💉Notably, the lawsuit is ongoing for one of the OB PATENT ('495) relating to "mfg. of bupivacaine multivesicular liposomes" which has an expiry of 22 Jan 2041. (Pacira vs e-venus Hengrui Pharma) #newsupdate #patent #Bupivacaine #liposome #injection #ANDA #generic #pharma #healthcare #approval
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic
marketwatch.com
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/Nbp2qu
To view or add a comment, sign in
-
Episode 20 of #AstonishingHealthcare is packed with information about #drugprices and the forces that drive them in the United States. It was a minor miracle that schedules lined up for this one, and A. J. Loiacono and Antonio Ciaccia could join us to share their insights and explain why #NADAC is a "ray of sunshine" (i.e., source of #truth) in an otherwise murky but essential part of the pharmaceutical #supplychain. They discuss: ↘️ The changes to NADAC and why we're seeing [substantial] deflationary pressure 💡 The unique aspects of NADAC that make it broadly helpful to the market 🔎 Why drug prices behave unlike the price of any other goods in our economy 🎧 Listen to the full episode here: https://okt.to/am1IZV
To view or add a comment, sign in